JOINN attended the outcome conference of Beijing Technology Innovation Action Plan (2014-2017)
2021-05-26
On July 8, Beijing Municipal Information Office and Beijing Municipal Commission of Science and Technology jointly held a special series of achievements conference on the leapfrog development of biomedical industry of Beijing Technology Innovation Action Plan (2014-2017). Beijing Municipal Government launched the Beijing Bio-pharmaceutical Industry Leap-Over Development Project (" G20 Project ") in 2010. According to the 80-20 rule, the meaning of "G20" is to focus on and serve the development of key leading enterprises in the industry, and play their leading role in promoting the comprehensive leap-forward innovation and development of Beijing's biomedical industry.
In the 12th Five-year period, JOINN completed the internationalization of the construction of modern pharmaceutical non-clinical research and the platform. As the first batch of the G20, in 2014, with the sport of the Beijing municipal science and technology commission, JOINN built a platform on nervous system drugs such as key technology of preclinical evaluation, which includes the establishment of techniques and methods for the evaluation of nervous system drugs and the establishment of relevant animal disease models. Based on the accumulation of early experiments and the strong support of Beijing Municipal Commission of Science and Technology, JOINN's Alzheimer's disease treatment drug evaluation platform has been preliminarily established. So far, three rodent models of Alzheimer's disease have been established. At the same time, JOINN also established a series of evaluation systems ranging from behavioral science to pathology and molecular biology, and established a continuous drug administration system for experimental large and small animals. JOINN ophthalmic laboratory has been equipped with a series of eye surgery and inspection equipment.
To date, JOINN has supported more than 130 innovative drug varieties from domestic and foreign customers to apply for registration in the US FDA, and supported relevant varieties to enter clinical trials in the US. With the expansion of facilities, further improvement of instruments and equipment, and the expansion of talent team, JOINN has established a large-scale evaluation service capability, which has strongly supported the development of new drug research and development in China.